Author

Tarek Abdelfatah

Nottingham University Hospitals NHS TrustORCID 0000-0002-4746-9960Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:protein structure prediction· 1 Assay:scRNA-seq· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

Alex Jordan· 2 shared Kairbaan Hodivala‐DilkeiD· 2 shared Katie Baird· 2 shared Vimala AnthonydhasoniD· 2 shared Anita E. GrigoriadisiD· 1 shared Eleni ManiatiiD· 1 shared Elien HeyleniD· 1 shared Gabriela D’AmicoiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alex Jordan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

β3-Integrin controls pericyte metabolic states and shapes tumour-stromal metabolic crosstalk in breast cancer

Elien Heylen, Alex Jordan, Katie Baird, Gabriela D’Amico, Vimala Anthonydhason, Valle Morales, Vinothini Rajeeve, Pedro Casado, Pedro R. Cutillas, Tarek Abdelfatah, Katiuscia Bianchi, Kairbaan Hodivala‐Dilke

This study identifies two β3-integrin-dependent metabolic states in pericytes and shows their impact on tumour-stromal metabolic interactions in breast cancer.

bioRxiv · Sep 25, 2026 · PreprintCancer Biology

Mural β3-integrin signposts Stroma6, a gene signature predicting early relapse in low-risk and chemoresistant breast cancer

Alex Jordan, Vimala Anthonydhason, Katie Baird, Eleni Maniati, Janet Louise Jones, Isobelle Wall, Anita E. Grigoriadis, Jun Wang, Tarek Abdelfatah, Kairbaan Hodivala‐Dilke

The paper identifies a 6-gene stromal signature, Stroma6, that predicts early relapse in low-risk and chemoresistant breast cancer patients, independent of Oncotype DX results.

bioRxiv · Sep 16, 2026 · PreprintCancer Biology